Orchard Therapeutics plc - American Depositary Shares (ORTX)
ORTX moved a median of +0.06% 30 minutes after news, and +0.06% by the close. How ORTX actually reacts to news — the realized, point-in-time move the market made, measured across 80 labeled events over the last three years with zero look-ahead.
ORTX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.06% | 62% | 37 |
| 30-min | +0.06% | 66% | 38 |
| 60-min | +0.12% | 68% | 38 |
| to close | +0.06% | 61% | 38 |
| Middle 50% of ORTX reactions | 0.00% to +0.23% |
|---|---|
| Median reaction (30-min) | +0.06% |
| Measured reactions | 80 |
Half of all Orchard Therapeutics plc - American Depositary Shares news events land between +0.00% and +0.23% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when ORTX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ORTX's baseline. Nothing else.
Recent ORTX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Orchard Therapeutics Announces Multiple Presentations at ASGCT 2024 | Press release | GlobeNewswire | — | — | |
| Orchard Therapeutics Co-founder and Chief Executive Officer Dr. Bobby Gaspar Named to Inaugural 2024 TIME100 Health List | Press release | GlobeNewswire | — | — | |
| TIME Reveals the Inaugural TIME100 Health List of the World's Most Influential People in Health | Press release | PR Newswire | — | — | |
| Early Check Newborn Screening Study Taps Revvity to Provide Genome Sequencing | Press release | PR Newswire | — | — | |
| Orchard Therapeutics Outlines U.S. Launch Plans for Lenmeldy™ (atidarsagene autotemcel), the Only Approved Therapy for Children with Early-onset Metachromatic Leukodystrophy | Press release | GlobeNewswire | — | — | |
| FDA Approves First Gene Therapy for Children with Metachromatic Leukodystrophy | Press release | PR Newswire | — | — | |
| Orchard Therapeutics Receives FDA Approval of Lenmeldy™ (atidarsagene autotemcel), the Only Therapy for Eligible Children with Early-onset Metachromatic Leukodystrophy in the U.S. | Press release | GlobeNewswire | — | — | |
| CANNARAY LIMITED ANNOUNCES INTERNATIONAL MERGER WITH AQUALITAS INC. | Press release | PR Newswire | — | — | |
| Form 15-12G Orchard Therapeutics | SEC filing · Form 15-12G | SEC EDGAR | — | — | |
| Orchard Therapeutics Announces First Patient Randomized in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome | Press release | GlobeNewswire | — | — | |
| Orchard Therapeutics Announces Multiple Presentations at the 20th Annual WORLDSymposium | Press release | GlobeNewswire | — | — | |
| Form EFFECT Orchard Therapeutics | SEC filing · Form EFFECT | SEC EDGAR | — | — | |
| Orchard Therapeutics Announces Agreement with the Beneluxa Consortium Enabling Reimbursed Access to Libmeldy | Press release | GlobeNewswire | — | — | |
| Form 8-K Orchard Therapeutics For: Jan 24 | SEC filing · Form 8-K | SEC EDGAR | — | — | |
| Form POS AM Orchard Therapeutics | SEC filing · Form POS | SEC EDGAR | — | — | |
| Form S-8 POS Orchard Therapeutics | SEC filing · Form S-8 | SEC EDGAR | — | — | |
| Kyowa Kirin successfully completes acquisition of Orchard Therapeutics, a global gene therapy leader for rare diseases | Press release | GlobeNewswire | — | — | |
| Form 8-K Orchard Therapeutics For: Jan 22 | SEC filing · Form 8-K | SEC EDGAR | -0.08% | +0.30% | |
| Hematopoietic Stem Cell Transplantation Market to Grow Rapidly During the Study Period (2019-2032), Evaluates DelveInsight | Press release | PR Newswire | +0.06% | +0.00% | |
| Form 8-K Orchard Therapeutics For: Dec 19 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.12% | |
| Orchard Therapeutics Receives Swissmedic Approval for Libmeldy in Early-onset MLD | Press release | GlobeNewswire | +0.31% | +0.37% | |
| Form 8-K Orchard Therapeutics For: Dec 06 | SEC filing · Form 8-K | SEC EDGAR | +0.31% | +0.37% | |
| Form DEFA14A Orchard Therapeutics | SEC filing · Form DEFA14A | SEC EDGAR | +0.31% | +0.37% | |
| Form 8-K Orchard Therapeutics For: Nov 30 | SEC filing · Form 8-K | SEC EDGAR | +0.06% | +0.06% | |
| Form DEFA14A Orchard Therapeutics | SEC filing · Form DEFA14A | SEC EDGAR | +0.06% | +0.06% | |
| Orchard Therapeutics Receives U.S. FDA Fast Track Designation for OTL-203 in MPS-IH | Press release | GlobeNewswire | +0.00% | +0.06% | |
| Form 8-K Orchard Therapeutics For: Nov 15 | SEC filing · Form 8-K | SEC EDGAR | +0.37% | +1.68% | |
| Form DEFA14A Orchard Therapeutics | SEC filing · Form DEFA14A | SEC EDGAR | — | +0.37% | |
| Form DEFM14A Orchard Therapeutics | SEC filing · Form DEFM14A | SEC EDGAR | +0.19% | +0.19% | |
| Form 10-Q Orchard Therapeutics For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.13% | +0.06% | |
| Form 8-K Orchard Therapeutics For: Nov 13 | SEC filing · Form 8-K | SEC EDGAR | +0.13% | +0.06% | |
| Orchard Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Business Accomplishments | Press release | GlobeNewswire | +0.13% | +0.06% | |
| Form PREM14A Orchard Therapeutics For: Nov 03 | SEC filing · Form PREM14A | SEC EDGAR | -0.03% | +0.00% | |
| Form 8-K Orchard Therapeutics For: Oct 26 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -0.25% | |
| Orchard Therapeutics Announces Presentation of Additional Positive Data from Proof-of-concept Study of OTL-203 in MPS-IH at ESGCT 2023 | Press release | GlobeNewswire | +0.06% | +0.00% | |
| Orchard Therapeutics Announces Multiple Presentations at ESGCT 2023 | Press release | GlobeNewswire | +0.06% | -0.06% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ORTX section they belong to.
Where else ORTX is measured.
ORTX earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| TRACON PHARMS INC (TCON) | 81 | -0.63% | 16% |
| Homology Medicines, Inc. (FIXX) | 80 | -0.34% | 33% |
| Elite Pharmaceuticals, Inc. (ELTP) | 79 | -0.11% | 42% |
| Genetic Technologies Ltd - American Depositary Shares (GENE) | 79 | -0.05% | 33% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Orchard Therapeutics plc - American Depositary Shares's median reaction calculated?
Every labeled ORTX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 80 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 66% of ORTX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ORTX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.